Blockbuster sales prospects for Novartis AG’s cholesterol drug Leqvio (inclisiran) could be truncated by the Medicare price negotiation program established by the Inflation Reduction Act unless the law is amended, company executives acknowledged during their earnings presentation on 25 October.
Novartis’ Blockbuster Hopeful Leqvio Faces Perils Of Medicare’s Pricing Policy On Small Molecules
Medicare’s pending price negotiation program could impact the longevity of the Part B cholesterol drug Leqvio. Novartis CEO Vas Narasimhan notes the upcoming redesign of the Part D benefit could boost pricing pressure on Kisqali.
